+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Therapeutic Plasma Exchange - Global Strategic Business Report

  • PDF Icon

    Report

  • 245 Pages
  • May 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 4806278
The global market for Therapeutic Plasma Exchange was estimated at US$1.2 Billion in 2025 and is projected to reach US$2.0 Billion by 2032, growing at a CAGR of 7.6% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Therapeutic Plasma Exchange Market - Key Trends and Drivers Summarized

What Makes Therapeutic Plasma Exchange Critical in Modern Healthcare?

Therapeutic plasma exchange (TPE) has emerged as a life-saving procedure in treating various autoimmune diseases, hematological conditions, and neurological disorders. This procedure involves the removal of plasma from a patient's blood and its replacement with fresh plasma or a plasma substitute, which helps eliminate harmful antibodies and toxins. The increasing use of TPE in treating conditions such as Guillain-Barré syndrome, myasthenia gravis, and multiple sclerosis has underscored its critical role in healthcare. As awareness of the benefits of plasma exchange grows, more patients and healthcare providers are turning to this therapy, which has significantly expanded the therapeutic plasma exchange market in recent years.

How Are Different Applications and Technologies Driving the Market?

By technology, centrifugal-based and membrane filtration techniques are the most commonly employed methods, each offering distinct advantages. Centrifugal-based systems are widely used in treating neurological conditions, whereas membrane filtration is preferred for renal disorders and certain hematological diseases. Disease indication segments range from autoimmune disorders to blood dyscrasias and other critical illnesses. In terms of end-users, hospitals, specialty clinics, and blood donation centers dominate the market, with a growing number of outpatient facilities adopting TPE procedures for chronic disease management. The rising number of treatment options that incorporate TPE is expanding the market’s overall reach.

What Innovations Are Shaping the Future of Therapeutic Plasma Exchange?

Technological advancements have led to more efficient, safe, and user-friendly plasma exchange systems, making the procedure more accessible to healthcare providers. Automated apheresis devices, equipped with enhanced safety features, are increasingly becoming the standard of care, reducing procedure time and improving patient outcomes. Moreover, the integration of real-time monitoring and data analytics in TPE systems allows healthcare providers to customize treatments based on patient-specific conditions. Additionally, the growing trend of combining therapeutic plasma exchange with other treatment modalities, such as immunosuppressive therapies, is transforming the landscape of chronic disease management.

What Are the Key Drivers of Growth in the Therapeutic Plasma Exchange Market?

The growth in the therapeutic plasma exchange market is driven by several factors, including the rising prevalence of autoimmune diseases, the increased use of TPE in treating neurological conditions, and the growing number of regulatory approvals for novel plasma exchange devices. Technological innovations in apheresis devices, coupled with rising investments in healthcare infrastructure, are expanding the adoption of TPE. Additionally, increasing awareness among healthcare professionals about the benefits of early intervention with TPE in critical care settings is boosting the demand for plasma exchange. The expanding base of patients eligible for TPE, particularly in the treatment of rare and complex disorders, further propels market growth. Lastly, the development of portable and more cost-effective plasma exchange systems is expected to make this life-saving therapy more accessible, driving market expansion in the coming years.

Report Scope

The report analyzes the Therapeutic Plasma Exchange market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Disease Indication (Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders, Other Disease Indications); End-Use (Hospitals, Specialty Clinics, Ambulatory Surgery Centers).
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Apheresis Machines Component segment, which is expected to reach US$615.1 Million by 2032 with a CAGR of 7.2%. The Filters Component segment is also set to grow at 9.4% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $351.9 Million in 2025, and China, forecasted to grow at an impressive 7.4% CAGR to reach $356.8 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Therapeutic Plasma Exchange Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Therapeutic Plasma Exchange Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Therapeutic Plasma Exchange Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Asahi Kasei Medical Co., Ltd., B. Braun Melsungen AG, Baxter International, Inc., Fenwal, Inc., Fresenius SE & Co. KGaA and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Therapeutic Plasma Exchange market report include:

  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • Fenwal, Inc.
  • Fresenius SE & Co. KGaA
  • Haemonetics Corporation
  • HemaCare Corporation
  • Kawasumi Laboratories, Inc.
  • Terumo BCT, Inc.

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 193 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind
  • Global Economic Update
  • Therapeutic Plasma Exchange - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Growing Incidence of Autoimmune Diseases Propels Growth of Therapeutic Plasma Exchange Market
  • Rising Demand for Non-invasive Therapeutic Solutions Strengthens Adoption of Plasma Exchange
  • Increasing Application of Therapeutic Plasma Exchange in Neurological Disorders Expands Market Opportunity
  • Advances in Medical Device Technologies Drive the Efficiency of Plasma Exchange Systems
  • Growing Use of Therapeutic Plasma Exchange in Pediatric Applications Spurs Market Growth
  • Rising Focus on Plasma-based Treatments for Critical Illnesses Drives Adoption of Therapeutic Plasma Exchange
  • Technological Innovations in Apheresis Systems Generate Demand for Advanced Plasma Exchange Solutions
  • Increased Awareness of Plasma Donation Programs Expands Adoption of Plasma Exchange Treatments
  • Growing Number of Plasma Collection Centers Propels the Therapeutic Plasma Exchange Market
  • Integration of AI and Data Analytics in Plasma Exchange Systems Strengthens Operational Efficiency
  • Surge in Clinical Trials Exploring Plasma Exchange for Emerging Therapies Boosts Market Demand
  • Increasing Use of Plasma Exchange in Immunology and Hematology Drives Market Expansion
  • Rising Prevalence of Infectious Diseases Spurs Demand for Plasma-based Therapies
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Therapeutic Plasma Exchange Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Therapeutic Plasma Exchange by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Therapeutic Plasma Exchange by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Therapeutic Plasma Exchange by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Apheresis Machines Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Apheresis Machines Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Apheresis Machines Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Filters Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Filters Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Filters Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Columns & Adsorbers Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Columns & Adsorbers Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Columns & Adsorbers Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Disposables Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Disposables Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Disposables Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Software & Services Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Software & Services Component by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Software & Services Component by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Neurological Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Neurological Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Neurological Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 23: World Recent Past, Current & Future Analysis for Cardiovascular Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 24: World Historic Review for Cardiovascular Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 25: World 13-Year Perspective for Cardiovascular Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 26: World Recent Past, Current & Future Analysis for Hematology Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 27: World Historic Review for Hematology Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 28: World 13-Year Perspective for Hematology Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 29: World Recent Past, Current & Future Analysis for Renal Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 30: World Historic Review for Renal Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 31: World 13-Year Perspective for Renal Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 32: World Recent Past, Current & Future Analysis for Transplant Rejection Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 33: World Historic Review for Transplant Rejection Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 34: World 13-Year Perspective for Transplant Rejection Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 35: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 36: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 37: World 13-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 38: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 39: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 40: World 13-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 41: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 42: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 43: World 13-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 44: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 45: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 46: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Therapeutic Plasma Exchange Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
CANADA
JAPAN
  • Therapeutic Plasma Exchange Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
CHINA
  • Therapeutic Plasma Exchange Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
EUROPE
  • Therapeutic Plasma Exchange Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
FRANCE
  • Therapeutic Plasma Exchange Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
GERMANY
  • Therapeutic Plasma Exchange Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
ITALY
UNITED KINGDOM
  • Therapeutic Plasma Exchange Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
REST OF EUROPE
ASIA-PACIFIC
  • Therapeutic Plasma Exchange Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
REST OF WORLD
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • Fenwal, Inc.
  • Fresenius SE & Co. KGaA
  • Haemonetics Corporation
  • HemaCare Corporation
  • Kawasumi Laboratories, Inc.
  • Terumo BCT, Inc.

Table Information